Baxter recalls heparin on adverse events

More than 100 allergic reactions, including one possible death, prompted Baxter International to recall its anti-clotting drug heparin. The move affects nine manufacturing lots, or thousands of doses of the injectable med.

Since January 1, 150 patients reported possible reactions to the drug, including nausea, vomiting, dizziness, fainting, and throat swelling. One reported death "may be associated" with heparin as well. In contrast, the company typically receives 60 to 70 reports of adverse events each year, Baxter officials said.

The company isn't sure how many doses from the nine lots have been given to patients, but they were distributed to hospitals across the country--where even now, pharmacy staffs are scanning shelves for the recalled vials.

- check out the release
- read this article from the Wall Street Journal

Related Articles:
Quaid sues Baxter over Heparin. Report
Heparin overdose at Cedars-Sinai. Report
Third baby dies at IN hospital. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.